This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Tafamidis
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<scene name='10/1006890/Overall/1'>Wild-type transthyretin in complex with tafamidis</scene> ([[3tct]]). | <scene name='10/1006890/Overall/1'>Wild-type transthyretin in complex with tafamidis</scene> ([[3tct]]). | ||
| + | |||
| + | <scene name='10/1006890/Binding_site/1'>Tafamidis binding site</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:42, 6 November 2023
| |||||||||||
References
- ↑ "Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Retrieved 24 November 2019
- ↑ "Vyndaqel EPAR". European Medicines Agency. 16 October 2019. Retrieved 24 November 2019.
- ↑ "FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis". U.S. Food and Drug Administration. 14 September 2019. Archived from the original on 14 September 2019.
